image
Healthcare - Medical - Healthcare Information Services - NYSE - US
$ 58.85
5.08 %
$ 11.1 B
Market Cap
51.66
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one DOCS stock under the worst case scenario is HIDDEN Compared to the current market price of 58.9 USD, Doximity, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one DOCS stock under the base case scenario is HIDDEN Compared to the current market price of 58.9 USD, Doximity, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one DOCS stock under the best case scenario is HIDDEN Compared to the current market price of 58.9 USD, Doximity, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DOCS

image
$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
570 M REVENUE
19.98%
228 M OPERATING INCOME
39.01%
223 M NET INCOME
51.23%
273 M OPERATING CASH FLOW
48.44%
-29.3 M INVESTING CASH FLOW
-93.95%
-131 M FINANCING CASH FLOW
52.58%
138 M REVENUE
-17.98%
48.7 M OPERATING INCOME
-39.09%
62.5 M NET INCOME
-16.94%
98.5 M OPERATING CASH FLOW
51.08%
-24.5 M INVESTING CASH FLOW
58.47%
-29.7 M FINANCING CASH FLOW
-17.54%
Balance Sheet Doximity, Inc.
image
Current Assets 1.09 B
Cash & Short-Term Investments 916 M
Receivables 128 M
Other Current Assets 44.6 M
Non-Current Assets 176 M
Long-Term Investments 0
PP&E 22.5 M
Other Non-Current Assets 153 M
72.42 %10.15 %3.53 %12.11 %Total Assets$1.3b
Current Liabilities 156 M
Accounts Payable 1.36 M
Short-Term Debt 2.21 M
Other Current Liabilities 153 M
Non-Current Liabilities 25.4 M
Long-Term Debt 10.2 M
Other Non-Current Liabilities 15.2 M
84.04 %5.61 %8.39 %Total Liabilities$181.7m
EFFICIENCY
Earnings Waterfall Doximity, Inc.
image
Revenue 570 M
Cost Of Revenue 55.9 M
Gross Profit 515 M
Operating Expenses 284 M
Operating Income 228 M
Other Expenses 4.62 M
Net Income 223 M
600m600m500m500m400m400m300m300m200m200m100m100m00570m(56m)515m(284m)228m(5m)223mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
90.20% GROSS MARGIN
90.20%
39.94% OPERATING MARGIN
39.94%
39.13% NET MARGIN
39.13%
20.62% ROE
20.62%
17.65% ROA
17.65%
17.37% ROIC
17.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Doximity, Inc.
image
300m300m250m250m200m200m150m150m100m100m50m50m00202020202021202120222022202320232024202420252025
Net Income 223 M
Depreciation & Amortization -996 K
Capital Expenditures 0
Stock-Based Compensation 72.4 M
Change in Working Capital 0
Others 0
Free Cash Flow 273 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Doximity, Inc.
image
Wall Street analysts predict an average 1-year price target for DOCS of $52.9 , with forecasts ranging from a low of $38 to a high of $70 .
DOCS Lowest Price Target Wall Street Target
38 USD -35.43%
DOCS Average Price Target Wall Street Target
52.9 USD -10.18%
DOCS Highest Price Target Wall Street Target
70 USD 18.95%
Price
Max Price Target
Min Price Target
Average Price Target
90908080707060605050404030302020Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Doximity, Inc.
image
Sold
0-3 MONTHS
6.7 M USD 3
3-6 MONTHS
87.6 M USD 6
6-9 MONTHS
6.9 M USD 3
9-12 MONTHS
4.83 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. globenewswire.com - 1 week ago
Doximity Declines 4.4% in a Month: How to Play the Stock Now? Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EBITDA margin. For fiscal 2025, revenues totaled $570.4 million, up 20% year over year, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55%. zacks.com - 1 week ago
Dr Martens surges 23% as investors lace up for recovery story Shares in Dr Martens PLC (LSE:DOCS) jumped 23% on Thursday after the bootmaker delivered a better-than-expected full-year update and signalled a shift towards stabilisation and future growth, giving investors reason to believe the worst may be behind it. The British brand, known for its chunky leather boots, reported adjusted pre-tax profits of £34.1 million for the year to March, around £2 million ahead of consensus and squarely in line with Peel Hunt's forecast. proactiveinvestors.co.uk - 1 week ago
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from £97.2 million, the boot brand said in the results statement. proactiveinvestors.co.uk - 1 week ago
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach. 247wallst.com - 1 week ago
Doximity Rides on Telehealth Demand: Will This Drive Sales Further? DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs. zacks.com - 1 week ago
Which Telehealth Stock Should You Be Targeting? Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform. schaeffersresearch.com - 1 week ago
Dr Martens interims a first test for new CEO after shares stumble to all-time low Dr Martens PLC (LSE:DOCS) shares stumbled to a new all-time low below 50p last month after the US tariff announcement, but have been tiptoeing higher in the run-up to interim results due next Thursday, 5 June.  Back in January, the boot-maker flagged "good progress" in its turnaround after revenue ticked up 3% on a constant currency basis during the third quarter, aided by stronger American and Asia Pacific sales, offsetting a decline in Europe due to strong promotional activity from rivals in December. proactiveinvestors.co.uk - 2 weeks ago
Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Doximity, Inc. (NYSE: DOCS) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors. globenewswire.com - 3 weeks ago
Doximity to Present at the William Blair 45th Annual Growth Stock Conference SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025 at 4:40 p.m. Central Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties a. businesswire.com - 3 weeks ago
Doximity: A Closer Look at Its Investment Potential Explore the exciting world of Doximity (DOCS -1.43%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! fool.com - 3 weeks ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm NEW YORK , May 19, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company's business and operations. prnewswire.com - 3 weeks ago
8. Profile Summary

Doximity, Inc. DOCS

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 11.1 B
Dividend Yield 0.00%
Description Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact 500, 3rd Street, San Francisco, CA, 94107 https://www.doximity.com
IPO Date June 24, 2021
Employees 827
Officers Mr. Jeffrey A. Tangney Co-Founder, Chief Executive Officer & Chairperson Mr. Jey Balachandran Chief Technology Officer Dr. Nate Gross M.D. Co-Founder & Chief Strategy Officer Ms. Shari Buck Co-founder and SVice President People & Ops Mr. Perry Scott Gold Head of Investor Relations Mr. Bruno Miranda Senior Vice President of Engineering Ms. Anna Bryson Chief Financial Officer Ms. Jennifer W. Chaloemtiarana J.D. General Counsel & Corporate Secretary Mr. Craig A. Overpeck Senior Vice President of Commercial Operations Mr. Joel Davis Senior Vice President of Product